Aparna Parikh: Thrilled to launch this initiative aimed to reverse early recurrences of cancer
Aparna Parikh posted the following on LinkedIn:
“We are thrilled to launch this initiative bringing together stakeholders, including academic investigators, community investigators, patients, regulators, pharma, and diagnostics to reverse early recurrences and cure more patients.”
Quoting Broad Institute of MIT and Harvard:
“Standard clinical trials for cancer drugs are expensive, lengthy, and often focused on advanced disease in which cures are unlikely. Arielle Medford, Ariel Carmeli, Alex Ritchie, Eric Lander, and Aparna Parikh propose a standing clinical trials platform to advance development of adjuvant therapies that prevent recurrence. Through this platform, patients after curative-intent therapy who show early molecular evidence of recurrence, based on circulating tumor DNA, would be invited to enroll in clinical trials that could be smaller and faster than conventional adjuvant trials. Read more in Nature Reviews Cancer.”
A standing platform for cancer drug development using ctDNA-based evidence of recurrence
Authors: Arielle J. Medford, Ariel B. Carmeli, Alexandra Ritchie, Nikhil Wagle, Levi Garraway, Eric S. Lander & Aparna Parikh.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023